Title: Serrated polyposis syndrome: defining the epidemiology and predicting the risk of
dysplasia
Version: 1 Date: 06 Oct 2023
Reviewer:  Priyanka Kanth
Reviewer's report:
This is a retrospective single center study defining epidemiology of serrated polyposis syndrome
from an Australian cohort.  The study defines the prevalence of SPS in the population studied.
The data was collected prospectively from 2015 to 2021. The strength of the study is more recent
analysis of data when endoscopist/pathologist have better sense of diagnosis of SPS.
I have following comments.
1) There are other studies with prevalence data from other cohorts with similar findings
suggestive of serrated polyposis syndrome to be underdiagnosed.  Irrespective, having more
cohorts describing results would be good.
2) There are too many figures/tables.  Many of the figures can be combined to provide a concise
presentation.
3) Reword/rewrite discussion suggesting that prevalence of SPS is not well understood.  We
have data from UK, Netherlands and some US data that has been previously described. I would
add any prior prevalence data from Australian cohort in reference (refer to work done by Daniel
Buchanan/ Joanne Young). I would suggest rewording the strength ‘largest reported single center
cohort of SPS’. Cite other studies from Australia (PMID: 28979711)
4) SPS surveillance recommendation in the US is 1-3 years (per NCCN). I would cite this for
the US based readers.
Title: Serrated polyposis syndrome: defining the epidemiology and predicting the risk of
dysplasia
Version: 1 Date: 06 Oct 2023
Reviewer:  Priyanka Kanth
Reviewer's report:
This is a retrospective single center study defining epidemiology of serrated polyposis syndrome
from an Australian cohort.  The study defines the prevalence of SPS in the population studied.
The data was collected prospectively from 2015 to 2021. The strength of the study is more recent
analysis of data when endoscopist/pathologist have better sense of diagnosis of SPS.
I have following comments.
1) There are other studies with prevalence data from other cohorts with similar findings
suggestive of serrated polyposis syndrome to be underdiagnosed.  Irrespective, having more
cohorts describing results would be good.
2) There are too many figures/tables.  Many of the figures can be combined to provide a concise
presentation.
3) Reword/rewrite discussion suggesting that prevalence of SPS is not well understood.  We
have data from UK, Netherlands and some US data that has been previously described. I would
add any prior prevalence data from Australian cohort in reference (refer to work done by Daniel
Buchanan/ Joanne Young). I would suggest rewording the strength ‘largest reported single center
cohort of SPS’. Cite other studies from Australia (PMID: 28979711)
4) SPS surveillance recommendation in the US is 1-3 years (per NCCN). I would cite this for
the US based readers.
Please review this paper.
user
Title: Serrated polyposis syndrome: defining the epidemiology and predicting the risk of
dysplasia
Version: 1 Date: 06 Oct 2023
Reviewer:  Priyanka Kanth
Reviewer's report:
This is a retrospective single center study defining epidemiology of serrated polyposis syndrome
from an Australian cohort.  The study defines the prevalence of SPS in the population studied.
The data was collected prospectively from 2015 to 2021. The strength of the study is more recent
analysis of data when endoscopist/pathologist have better sense of diagnosis of SPS.
I have following comments.
1) There are other studies with prevalence data from other cohorts with similar findings
suggestive of serrated polyposis syndrome to be underdiagnosed.  Irrespective, having more
cohorts describing results would be good.
2) There are too many figures/tables.  Many of the figures can be combined to provide a concise
presentation.
3) Reword/rewrite discussion suggesting that prevalence of SPS is not well understood.  We
have data from UK, Netherlands and some US data that has been previously described. I would
add any prior prevalence data from Australian cohort in reference (refer to work done by Daniel
Buchanan/ Joanne Young). I would suggest rewording the strength ‘largest reported single center
cohort of SPS’. Cite other studies from Australia (PMID: 28979711)
4) SPS surveillance recommendation in the US is 1-3 years (per NCCN). I would cite this for
the US based readers.
assistant